Nature Communications published a mechanistic study identifying the m6A RNA demethylase ALKBH5 as a driver of cancer stemness and chemoresistance in colorectal cancer; genetic or pharmacologic targeting reduced tumor‑initiating capacity and sensitized models to chemotherapy. The authors showed that ALKBH5 regulates mRNA stability of stemness‑associated transcripts. m6A refers to methylation on messenger RNA that alters transcript stability and translation; targeting m6A regulators is an emerging therapeutic strategy in oncology. The findings provide a preclinical rationale for developing ALKBH5 inhibitors or combination regimens to overcome resistance in colorectal cancer and highlight an RNA‑modification axis as a tractable vulnerability.